ArticleSkeletal radiology2026
Apparent diffusion coefficient metrics for treatment response assessment in soft tissue sarcoma: Reproducibility and prognostic value of whole-tumor and sub-regional analysis.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the inter-observer reproducibility and predictive value of apparent diffusion coefficient (ADC) metrics derived from diffusion-weighted MRI for assessing histopathologic response to neoadjuvant radiotherapy in soft tissue sarcoma (STS). MATERIALS AND
methodsThis retrospective, single-institution cohort study included 23 patients with histologically proven STS treated with neoadjuvant radiotherapy. Patients underwent 1.5 T or 3.0 T MRI, including diffusion-weighted sequences (b = 200, 800 s/mm
resultsSingle-timepoint ADC measurements demonstrated high inter-observer reproducibility, particularly for mean tumor ADC (ICC = 0.91-0.95). Reproducibility for ADC changes over time was lower; agreement for mean tumor ADC (ICC = 0.79) outperformed subregional values (ICC = 0.06-0.63). Post-treatment mean tumor ADC was significantly elevated in responders (median 2.39 × 10⁻
conclusionPost-treatment ADC measurements were highly reproducible and best predicted pathological response in our cohort. Longitudinal changes were less robust and require further research into the effect of standardized DWI protocols and more reliable techniques for sub-regional analysis.
Indexed as
Identifiers
42530616What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.